TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a digital health artificial intelligence company focused on brain health, today announced a test launch of CERVAI™, a world-first consumer brain health and wellness AI solution, at the University of Miami Comprehensive Center for Brain Health. The initial focus will be evaluating the brain health assessment portion of CERVAI™, which scores brain health by taking a clinically validated assessment for brain resilience, vulnerability and performance functions.
Figure: Screenshot of CERVAI™ online portal
CERVAI™’s brain health assessment, developed by researchers led by Dr. James E Galvin, M.D., M.P.H at the University of Miami Miller School of Medicine, is designed to assess a patient’s risk for developing Alzheimer’s disease (“AD”) and other neurological issues, through an advanced series of tests that determine the risk for dementia by combining three measures — a Resilience Index (“RI”), a Vulnerability Index (“VI”) and a Number-Symbol Coding Task (“NSCT”). The results, when combined, help assess the risk for developing AD and other related conditions. Essentially, it is intended to “take a snapshot” of a patient’s brain health.
In a cross-sectional study, Galvin and colleagues evaluated 230 participants (71 controls, 71 with mild cognitive impairment, 88 with AD and related disorders). Researchers determined VI and RI scores from physical assessments, lifestyle questionnaires, demographics, medical history and neuropsychological examination, including the NSCT. Results showed that participants with abnormal test scores were 95.7% likely to be impaired, with a misclassification rate of 9.7%. The platform outperformed the Montreal Cognitive Assessment with a high level of accuracy (area under the curve = 0.923 ± 0.053)¹.
Fabio Chianelli, Chairman and CEO of DiagnaMed, commented: “We are creating momentum for the upcoming commercial launch of CERVAI™, a world-first consumer brain health and wellness solution that estimates brain age and provides a brain health score, and being tested at a reputable University brain health center serves as a validation of CERVAI™’s potential in providing a unique service to clinics seeking a solution that helps bridge the gaps in physical and cognitive health while enhancing client engagement and design personalized interventions in improving overall brain health."
The CERVAI™ Brain Health test pilot program continues to be open to a select 25 clinics in the U.S. and Canada. Ideal clinics for the pilot program must focus on health and wellness, sports and physical therapy, mental health, chiropractic care, or clinical research for neurological and cognitive disorders.
For more information about CERVAI™ and joining the pilot program, visit https://www.diagnamed.com/hcpartner.
About CERVAI™ Brain Health Platform
Based on research and development at Drexel University and the University of Miami, CERVAI™ combines a Brain Age™ Estimation and Brain Health Assessment tool with the aim to ‘raise a red flag’ for potential brain health issues. CERVAI™ can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals. Brain age is estimated by collecting neural activity data of the brain with a low-cost and easy-to-use electroencephalogram (“EEG”) headset and calculating the data with a proprietary machine-learning model. In addition, CERVAI™ can assess if a person has a healthy brain or is in the early stage of cognitive decline. Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions. Individuals can seek out personalized diagnostics and interventions, such as medication or lifestyle changes, that may help to decrease the development or progression of cognitive decline.
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a digital health artificial intelligence company focused on commercializing CERVAI™, a world-first consumer brain health and wellness AI solution that aims to ‘raise a red flag’ for potential brain health issues by estimating brain age and providing a brain health score. Visit DiagnaMed.com.
For more information, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “estimate”, “anticipate”, “intend”, “believe”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the year ended September 30, 2023 (“MD&A”), dated January 29, 2024,which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
Sources:
- Kleiman, Michael J et al. “The Brain Health Platform: Combining Resilience, Vulnerability, and Performance to Assess Brain Health and Risk of Alzheimer's Disease and Related Disorders.” Journal of Alzheimer's disease: JAD vol. 90,4 (2022): 1817-1830. doi:10.3233/JAD-220927
A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/6bcce004-2b84-4019-89cd-4803b483a928
